The National Cancer Institute estimates about 1,638,910 new cancer cases are expected to be diagnosed in 2012. In 2012, about 577,190 A mericans are expected to die of cancer, more than 1,500 people a day. Cancer is the second most common cause of death in the US. By 2030, the global burden is expected to grow to 21.4 million new cancer cases and 13.2 million cancer deaths simply due to the growth and aging of the population, as well as reductions in childhood mortality and deaths from infectious diseases in developing countries 2 . The primary modalit ies of cancer treatment are surgery, chemotherapy, and radiotherapy; these may be used alone or in combination. Surgical treat ment 3,4 depends on the stage of cancer, the organ affected and the patient condition. In surgically treated patients, pain relief can often be achieved and long term neurological stabilizat ion tends to persist more often that it does with conservatively treated patients. Surgical intervention may be appropriate for patients with advanced disease for avoiding urgent lifethreatening symptoms or serious functional disorders that annoys patients daily life, but surgical treat ment for elderly cancer patients should be carefully considered after weighing the risk of post operative mortality, morb idity, functional deterioration due to the surgery and speculated life surgery. 
COMB INATION CANCER THERAPY:
Chemotherapy drugs are most effective when given in combination (co mbination chemotherapy). The rationale for comb ination chemotherapy is to use drugs that work by different mechanisms of action, thereby decreasing the likelihood that resistant cancer cells will develop. When drugs with different effects are combined, each drug can be used at its optimal dose, without intolerable side effects.
Combinations used in breast Cancer:
Breast cancer (malignant breast neoplasm) is a type of cancer originating fro m breast tissue, most commonly fro m the inner lin ing of milk ducts or the lobules that supply the ducts with milk 76 . Worldwide, breast cancer comprises 22.9% of all cancers (excluding non-melano ma skin cancers) in women 77 . In 2008, breast cancer caused 458,503 deaths worldwide (13.7% of cancer deaths in wo men) 77 . Breast cancer is more than 100 t imes more common in wo men than breast cancer in men, although males tend to have poorer outcomes due to delays in diagnosis 77 -79 . An estimated 226,870 new cases of invasive breast cancer are expected to occur among wo men in the US during 2012; about 2,190 new cases are expected in men.
Nabholtz JM suggested that the taxanes and anthracyclines have emerged as the most active agents for treating women with advanced breast cancer 80, 81 . Phase II trials of the docetaxel co mb inations with either doxorubicin or epirubicin showed high activity, with acceptable tolerability in patients with metastatic breast cancer. Consequently, three randomized trials have compared docetaxel-anthracycline-based regimens with standard anthracycline-based polychemotherapies as firstline therapy for wo men with advanced breast cancer. Therefore, docetaxel-anthracycline combinations represent a validated option in first-line treat ment for wo men with advanced breast cancer, and are further evaluated as adjuvant treatment for early stage breast cancer. Joensuu H et al showed that adjuvant treatment with docetaxel, as compared with vinorelbine, improves recurrence-free survival in wo men with early breast cancer, when docetaxel co mpared with vinorelb ine for the adjuvant treatment of early breast cancer 82 -88 , a short course of trastuzumab ad min istered concomitantly with docetaxel or vinorelbine is effect ive in wo men with breast cancer who have an amplified HER2/neu gene. Pretreat ment with dexamethasone increases antitumor activity of carboplatin and gemcitabine 89 . To our knowledge, this is the first report that DEX significantly enhances the antitumor activity of carboplatin and gemcitabine and increases their accumulat ion in tumors. These results provide a basis for further evaluation of DEX as a chemosensitizer in patients. Eichhorn PJ et al identified the tumor suppressor PTEN as a modulator of lapatinib sensitivity in vitro and in vivo 90 . Their data show that deregulation of the PI3K pathway, either through loss-of-function mutations in PTEN or dominant activating mutations in PIK3CA, leads to lapatinib resistance, which can be effectively reversed by NVP-BEZ235. A recent phase III trial demonstrated that the combination of capecitabine (Xeloda) and docetaxel (Taxotere) significantly improved objective tumor response rate, time to disease progression, and overall survival compared with single-agent docetaxel in anthracycline-pretreated patients with advanced breast cancer 91 . Green tea polyphenol EGCG synergistically sensitized breast cancer cells to paclitaxel in v itro and in vivo 92 . EGCG in co mb ination with paclitaxel significantly induced 4T1 cells apoptosis compared with each single treatment. EGCG may be used as a sensitizer to enhance the cytotoxicity of paclitaxel.
Combinations used in Prostate Cancer:
Prostate cancer is the most common hu man visceral malignancy and the third most common cause of cancerrelated deaths among men in the Westernized wo rld 93 . Autopsy studies show that men in the fourth decade of life have a one-third risk of harboring small carcino mas 94 . Death rates from prostate cancer vary across the globe, with Westernized nations having the highest risk of incidence and death and Asian nations having the lowest 95 .
Many tumors constitutively express high levels of the inducible form of p roinflammatory en zy me, cyclooxygenase-2 (COX-2) 96 . Co mb ination of Celeco xib and docetaxel inhib ited COX-2 activity and associated alteration in cell death signaling, a potential clin ical use of combined dosing of COX-2 inhibitors and cytotoxic drugs at lower, nontoxic dose than currently used to treat advanced prostate cancer. McCubrey JA et al isolated cell with the cancer init iating cell (CIC) phenotype from PC3 cells 97 . Low doses of genistein can increase the sensitivity of prostate CICs to drugs such as docetaxel and cyclopamine, two drugs either used or under consideration for prostate cancer therapy. The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizu mab in preclin ical models of prostate cancer 98 . The objective of the present study was to assess the antitumor effects of PG11047 alone and in combination with approved anti-cancer agents. Another study showed that demonstrate the potential anticancer efficacy of genistein-topotecan combination in LNCaP prostate cancer cells and the mechanism of the combination treatment 99 . Treatments involving genisteintopotecan combination may prove to be an attractive alternative phytotherapy or adjuvant therapy for prostate cancer. An exploratory analysis of phase III trial participants found a substantial survival benefit to receiving docetaxel some months after sipuleucel-T 100 . Sipuleucel-T is an active immunotherapy that triggers Tcell responses against prostate cancer. This trial highlights major unresolved questions concerning th e optimu m choice, dosing, and timing of chemotherapy relative to active immunotherapy. Stearns ME and Wang M have examined whether epigallocatechin-3-gallate (EGCG), and extract of green tea, in combination with taxane (i.e., paclitaxel and docetaxel), exe rts a synergistic activity in blocking hu man prostate PC-3M L tumor cell growth in vitro and in vivo 101 .
The overall chance of death from prostate cancer, even among Westernized nations that have not historically treated the disease for cure, is 3.5% to 4% 102 . Given the large d iscordance between histologic incidence and death, there is great potential for overdetection and overtreatment. This is even more relevant as treatmentrelated morb idit ies associated with prostate cancer treatment can impact urinary function, sexual function, and quality of life 103 . Disease prevention thus offers an attractive paradigm for addressing this important public health problem.
Combinations used in Col on Cancer:
An estimated 103,170 cases of colon and 40,290 cases of rectal cancer are expected to occur in 2012. Colon cancer, the fourth most common cancer in the world, is one of the leading causes of cancer death in both men and women in Western countries, including the USA 104, 105 . An expert panel assembled by the American Ins titute for Cancer Research/World Cancer Research Foundation came to a scientific consensus that there is evidence for a correlation between a high intake of saturated fats (and/or animal fat) and colon cancer risk 106 .
Schröder CP, Maurer HR demonstrated in vitro, that pretreatment of human LS 174T co lon cancer cells with nontoxic concentrations of tributyrin augments the sensitivity to spontaneous NK cell activ ity two-fold 107 . However, when NK cells have been activated with an optimized co mbination of IL-2 and IL-12, the immunocytotoxicity increases up to five-fold (fro m 14% to 70%), versus a 3.8-fo ld increase against untreated cancer cells. These data suggested a synergistic link between induction of tumor cell differentiat ion and immunological defense mechanisms that may provide a rational basis for the imp rovement of clinical protocols, especially for colon cancer. In vitro 108 , viable cell gro wth was determined by trypan blue exclusion assay and cell death was investigated by flow cytometry. ALA (50 µg/ml) and HESW (E1, EFD = 0.22 mJ/ mm², 1000 shots or E2, EFD = 0.88 mJ/ mm², 500 shots) showed a significant reduction of cancer cell proliferation at day 3 compared to cells exposed to ALA (p < 0.01) or HESW (p < 0.001) alone. In v ivo, apoptosis detection was carried out by TUNEL assay, the pro-apoptotic gene Bad and Bcl-2 mRNA expression was evaluated by quantitative SYBR Green real time RT -PCR and cleavage of poly (ADP-ribose)-polymerase (PARP) was investigated by Western Blotting. The interaction between HESW and ALA is then effective in inducing apoptosis on a syngeneic colon cancer model 108 . Antitumor activities of carboplatin and gemcitabine with or without DEX pretreatment were determined in six murine-human cancer xenograft models, including cancers of colon (LS174T) 89 . Although DEX alone showed minimal antitumor activity, DEX pretreatment significantly increased the efficacy of carboplatin, gemcitabine, or a combination of both drugs by 2-4-fold in all xenograft models tested and increased their accumulation in tumors. Maju mdar AP et al described that the combination of curcumin and resveratrol was found to be more effective in inhibit ing growth of p53-positive (wt) and p53-negative colon cancer HCT-116 cells in v itro and in vivo in SCID xenografts of colon cancer HCT-116 (wt) cells than either agent alone 110 . In vitro studies have further demonstrated that the combinatorial treat ment caused a greater inhibition of constitutive activation of EGFR and its family members as well as IGF-1R. Their current data suggest that the combination of curcu min and resveratrol could be an effective preventive/therapeutic strategy for colon cancer. In other review Felth J et al described that some cardiac glycosides (digitoxin, digo xin, Convallato xin) have been reported to exhibit cytotoxic activity against several different cancer types like colorectal cancer etc 111 . The combination of oxaliplatin and oxaliplatin exh ibited synergism including the otherwise highly drug-resistant HT29 cell line. These findings demonstrate that such substances may exh ibit significant activity against colorectal cancer cell lines.
Combinations used in lung cancer:
Lung cancer is the leading cause of cancer-related death in the world and can be broadly classified into small cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) 112 . NSCLC accounts for approximately 85% of all lung cancers 113 , and unlike SCLC, NSCLC is less sensitive to chemotherapeutic agents. Natural co mpounds in combination with chemotherapy agents enhance anticancer activities of drugs and reduce their toxicity. Milczarek M et al determined an effect of isothiocyanates and 5-fluorouracil used alone or in combination (in sequential or co-admin istrative treatments) on normal cell lines -V79 114 . There was observed an antagonistic effect which was mainly dependent on the cell cycle distribution and their combination increased the cell number in the S phase. Another combination therapy using paclitaxel (PTX) as chemotherapeutic molecule and theophylline (TH) as differentiative agent in the prevention of metastasis in B16-F10 melano ma-bearing C57BL6/N mice. In vitro proliferation studies demonstrated that TH enhanced the antiproliferative effect of PTX. Th is study demonstrated that the simultaneous treatment of mice with TH and a low dose of PTX produced a similar anti-invasive effect than that caused by highly toxic PTX concentration 115 . Antitumor activities of carboplatin and gemcitabine with DEX pretreat ment were determined in human cancer xenograft models, including lung (A549 and H1299) cancer 89 . DEX pret reatment significantly increased tumor © 2011, JDDT. All Rights Reserved ISSN: 2250-1177 CODEN: JDDTAO carboplatin levels, including 200% increase in area under the curve, 100% increase in maximu m concentration, and 160% decrease in clearance. DEX pretreat ment similarly increased gemcitabine uptake in tumors. In other review PG11047 is a polyamine analog currently in Phase I trials for advanced cancer in co mbination with a number of approved anti-cancer agents 98 . The antitumor efficacy of PG11047 as a single agent, and in co mbination with cisplatin and bevacizu mab, was tested in models of lung (A549) cancer and the result that PG11047 potentiated the antitumor effect of cisplatin. Green tea is now recognized as the most effective cancer preventive beverage 116 . The synergistic enhancement of apoptosis and GADD153 gene expression in human non-small cell lung cancer cells by the combination of EGC G and celeco xib were mediated through the activation of the MAPK signaling pathway. This article reviews the synergistic enhancement of apoptosis, gene expression, and anticancer effects using various combinations of EGCG and anticancer drugs. Saha A et al studied the enhancing effects of EC on inductions of growth inhibit ion and apoptosis in human lung cancer cell lines PC-9 and A549 with curcumin. The comb ination similarly increased both apoptosis and expression of GA DD153 and GA DD45 genes, associated with their enhanced protein production 117 . This report is the first report on the enhancing effects of EC on curcumin, and the data suggest that EC plays a significant role in the enhancement of the cancer-preventive activity of curcumin in the diet.
CONCLUS ION:
Nu merous experimental, clinical, and epidemiologic studies indicate that combination of drugs particularly natural drug combination show promise as anticancer drugs chemotherapy. The clinical application of these combination drugs is still limited by the lack of randomized evidence of their efficacy and safety. The combination therapy is defin itely a pro mising area in chemotherapy to reduce the dose of anticancer drugs henceforth the adverse effects as well but more clinical studies are required.
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